Dibutyryl-cAMP Sodium salt hydrate

Catalog No. :
ACLESQ280
CAS No. :
123334-06-5
Molecular Formula :
C18H25N5NaO9P
Molecular Weight :
509.39

IUPAC Name:sodium (4aR,6R,7R,7aR)-6-(6-butyramido-9H-purin-9-yl)-7-(butyryloxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide hydrate

Dibutyryl-cAMP Sodium salt hydrate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameDibutyryl-cAMP Sodium salt hydrate
IUPAC Namesodium (4aR,6R,7R,7aR)-6-(6-butyramido-9H-purin-9-yl)-7-(butyryloxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide hydrate
MDL No.MFCD00149371
Molecular FormulaC18H25N5NaO9P
Molecular Weight509.39
SMILESCCCC(=O)NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H]2COP(=O)([O-])O[C@H]2[C@H]1OC(=O)CCC.O.[Na+]
InChI KeyMBIUSAASWSOYGU-VMZSDVDQSA-M
SynonymN-6,O-2'-DIBUTYRYLADENOSINE 3':5'-CYCLIC MONOPHOSPHATE SODIUM SALT 1H2O, 98%;N-6,O-2'-dibutyryladenosine 3':5'-cyclic monopho;N6,O-2-Dibutyryladenosine 3:5-cyclic monophosphate sodium salt monohydrate;N6,2'-0-DIBUTYRYLADENOSINE 3',5'-CYCLIC MONOPHOSPHATE SODIUM SALT MONOHYDRATE, 95%;N6,2'-O-Dibutyryladenosine 3',5'-cyclic monophosphate, sodium salt monohydrate,95%
CAS No.123334-06-5

Synthetic Route by SureRoute

1. ACLESQ280 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLESQ280 route product structure diagram
    ACLESQ280123334-06-5
Inquiry

2. ACLESQ280 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLESQ280 route product structure diagram
    ACLESQ280123334-06-5
Inquiry

Comments (0)